Table 1 Overview of reported cases with GABRG2(A106T) mutations.

Patient No	1 [19]	2 [19]	3 [28]	4 [28]	5 [28]	6 [28]	7 [29]	8 [29]	9 [50]
Sex	Female	Male	Female	Male	Female	Female	Female	Female	Female
Age at seizure onset	Day 1	3 months	4 months	6 weeks	Day 1	Day 2	Day 40	Day 2
Seizure types	GTCS,tonic, FS	Tonic, FS, atonic	GTCS, atonic	GTCS, FS	GTCS, FS, myoclonic	GTCS, FS, myoclonic	FS	FS; GTCS, SE
AED responses	LEV	No clear response	No clear response	No clear response	Pyridoxine OXC	LEV; OXC	VPA; OXC	TPM; LEV	No clear response
Seizure Outcomes	Seizure-free	Intractable	Intractable	Intractable	Intractable	Seizure-free	Seizure-free	Seizure-free	Intractable
MRI findings	Delayed myelination	Volume loss	Normal	Normal	Normal	Normal	Cortex dysplasia, delayed myelination	Normal
Visual impairment	No	No	Yes	No	Yes	Yes	No	No
Development	Delay	Delay	Delay	Delay	Delay	Delay	Delay	Delay

Underlining indicates treatment with clinical response.
GTCS generalized tonic-clonic seizure, FS focal seizure, SE status epilepticus, LEV levetiracetam, VPA valproic acid, TPM topiramate, OXC oxcarbazepine.

Quick links

Search